In this post in the Global Health Technologies Coalition’s “Breakthroughs” blog, Heather Ignatius, senior policy manager for the TB Alliance, writes that while “[t]he most recent WHO TB Control report noted that rates of [tuberculosis (TB)] declined this past year for the first time in decades, … TB remains one of the most devastating global health crises today, with ripple effects that extend beyond health to cripple prosperity and development of regions overwhelmed by the disease.” She highlights “the launch of a collaboration between four pharmaceutical companies, along with the TB Alliance and the World Health Organization (WHO), which enables information-sharing on TB drug candidates within their respective pipelines” and “aims to bring these groups together to quickly and collaboratively identify and develop the most promising new TB drug regimens, regardless of sponsor” (11/15).